Dr. Dees is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
170 Manning Dr, 3rd floor
Chapel Hill, NC 27599Phone+1 919-843-7714Fax+1 919-966-6735
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1996 - 1999
- Brigham and Women's HospitalResidency, Internal Medicine, 1993 - 1996
- Duke University School of MedicineClass of 1993
Certifications & Licensure
- NC State Medical License 1999 - 2022
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer Start of enrollment: 2018 Jun 21
Roles: Contact
Publications & Presentations
PubMed
- 1508 citationsThe Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesLisa A. Carey, E. Claire Dees, Lynda R. Sawyer, Lisa Gatti, Dominic T. Moore
Clinical Cancer Research. 2007-04-15 - 20 citationsChanging Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.Louisa A. Mounsey, Allison M. Deal, Kevin Keith, Julia M. Benbow, Shlomit S. Shachar
Clinical Breast Cancer. 2017-08-09 - 472 citationsPhase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases...Howard A. Burris, Herbert Hurwitz, E. Claire Dees, Afshin Dowlati, Kimberly L. Blackwell
Journal of Clinical Oncology. 2005-08-10
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: